Table 3.
Relationship between disease control and clinicopathologic factors
| Factors | Number of patients (%) | Disease control rate | P-value |
|---|---|---|---|
| Age (years) | |||
| < 75 | 84 (75.7%) | 45.2% (38/84) | 0.659 |
| ≥ 75 | 27 (24.3%) | 51.9% (14/27) | |
| Sex | |||
| Male | 91 (82.0%) | 45.1% (41/91) | 0.465 |
| Female | 20 (18.0%) | 55.0% (11/20) | |
| BMI (kg/m 2 ) | |||
| < 22 | 79 (71.2%) | 50.6% (40/79) | 0.294 |
| ≥ 22 | 32 (28.8%) | 37.5% (12/32) | |
| Primary-site resection | |||
| Yes | 52 (46.8%) | 50.0% (26/52) | 0.571 |
| No | 59 (53.2%) | 44.1% (26/59) | |
| Histology | |||
| Intestinal | 68 (61.3%) | 48.5% (33/68) | 0.557 |
| Diffused | 42 (37.8%) | 42.9% (18/42) | |
| Unclassified | 1 (0.9%) | 100% (1/1) | |
| Liver metastasis | |||
| Yes | 31 (27.9%) | 48.4% (15/31) | 1.000 |
| No | 80 (72.1%) | 46.3% (37/80) | |
| Peritoneal metastasis | |||
| Yes | 43 (38.7%) | 46.5% (20/43) | |
| No | 68 (61.4%) | 47.1% (32/68) | |
| Ascites > grade2 | |||
| Yes | 23 (20.7%) | 52.2% (12/23) | 0.642 |
| No | 88 (79.3%) | 45.5% (40/88) | |
| Number of metastatic sites | |||
| < 2 | 70 (63.1%) | 44.3% (31/70) | 0.556 |
| ≥ 2 | 41 (36.9%) | 51.2% (21/41) | |
| HER2 | |||
| Positive | 16 (14.4%) | 43.8% (7/16) | 0.793 |
| Negative | 90 (81.1%) | 47.8% (43/90) | |
| Unknown | 5 (4.5%) | 40.0% (2/5) | |
| irAE > grade 3 | |||
| Yes | 57 (51.4%) | 49.1% (28/57) | 0.448 |
| No | 54 (48.6%) | 57.4% (31/54) | |
| Serum albumin (g/dL) | |||
| < 3.5 | 55 (51.4%) | 52.7% (29/55) | 0.441 |
| ≥ 3.5 | 52 (48.6%) | 44.2% (23/52) | |
| CAR change | |||
| < 3.0 | 66 (72.5%) | 62.1% (41/66) | < 0.001 |
| ≥ 3.0 | 25 (27.5%) | 8.0% (2/25) | |
| PLR change | |||
| < 1.3 | 62 (57.9%) | 62.9% (39/62) | < 0.001 |
| ≥ 1.3 | 45 (42.1%) | 24.4% (11/45) | |
| NLR change | |||
| < 1.5 | 60 (56.1%) | 58.3% (35/60) | 0.011 |
| ≥ 1.5 | 47 (43.9%) | 31.9% (15/47) |
BMI: Body mass index
irAE: immune-related adverse event
CAR: C-reactive protein-to-albumin ratio
PLR: platelet-to-lymphocyte ratio
NLR: neutrophil-to-lymphocyte ratio
CAR change: CAR after the fourth administration of nivolumab divided by CAR before nivolumab administration
PLR change: PLR after the fourth administration of nivolumab divided by PLR before nivolumab administration
NLR change: NLR after the fourth administration of nivolumab divided by NLR before nivolumab administration